Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection

Transplant Infectious Disease

Volumn 15, Issue 1, 2013, Pages 34-41

  Momper, J D ^a   Zhao, Y ^b   Shapiro, R ^c   Schonder, K S ^b   Gao, Y ^b   Randhawa, P S ^d   Venkataramanan, R ^b,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

BK virus; Cidofovir; Kidney transplantation; Pharmacokinetics

Indexed keywords

ANTIEMETIC AGENT; CIDOFOVIR; COTRIMOXAZOLE; CYCLOSPORIN; PROBENECID; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BK VIRUS INFECTION; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EXCRETION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VIREMIA; VIRUS LOAD;

ADJUVANTS, PHARMACEUTIC; ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; BK VIRUS; CROSS-OVER STUDIES; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYOMAVIRUS INFECTIONS; PROBENECID; TUMOR VIRUS INFECTIONS; VIREMIA;

EID: 84873448710     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12014     Document Type: Article

References (32)

1. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15 (3): 324-332.
2. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26 (4): 671-673.
3. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13 (8): 2145-2151.
4. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67 (1): 103-109.
5. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006; 6 (9): 2000-2005.
6. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5 (3): 582-594.
7. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347 (7): 488-496.
8. Bronson JJ, Ferrara LM, Hitchcock MJ, et al. (S)-1-(3-hydroxy-2-(phosphonylmethoxy) propyl)cytosine (HPMPC): a potent antiherpesvirus agent. Adv Exp Med Biol 1990; 278: 277-283.
9. de Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31 (3): 165-172.
10. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008; 8 (7): 1413-1422.
11. Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005; 79 (1): 116-118.
12. Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 2008; 12 (7): 790-795.
13. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75 (1): 105-112.
14. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 1: 1025-1032.
15. Wu SW, Chang HR, Lian JD. The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 2009; 24 (3): 1034-1038.
16. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36 (2): 127-143.
17. Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 1996; 3: 153-161.
18. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther 1999; 65 (1): 21-28.
19. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995; 39 (6): 1247-1252.
20. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999; 56 (3): 570-580.
21. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; 44: 137-166.
22. Momper JD, Zhang S, Randhawa PS, Shapiro R, Schonder KS, Venkataramanan R. Determination of cidofovir in human plasma after low dose drug administration using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2010; 53 (4): 1015-1021.
23. Gilead Sciences. Cidofovir Package Insert. Foster City, CA: Gilead Sciences, 2000.
24. Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos 1996; 24 (3): 315-321.
25. Wolf DL, Rodriguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol 2003; 43 (1): 43-51.
26. Nadai M, Apichartpichean R, Hasegawa T, Nabeshima T. Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. J Pharm Sci 1992; 81 (10): 1024-1027.
27. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36 (2): 205-216.
28. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4 (7): 1-246.
29. Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 2011; 39 (8): 1363-1369.
30. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4 (10): 1551-1558.
31. Fujita T, Brown C, Carlson EJ, et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 2005; 15 (4): 201-209.
32. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 2011; 201: 29-104.